1. Home
  2. GEG vs PMVP Comparison

GEG vs PMVP Comparison

Compare GEG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Great Elm Group Inc.

GEG

Great Elm Group Inc.

HOLD

Current Price

$2.24

Market Cap

67.4M

Sector

Technology

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.28

Market Cap

66.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEG
PMVP
Founded
1994
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.4M
66.1M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
GEG
PMVP
Price
$2.24
$1.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.7K
407.4K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,974,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.70
N/A
52 Week Low
$1.80
$1.02
52 Week High
$3.14
$1.88

Technical Indicators

Market Signals
Indicator
GEG
PMVP
Relative Strength Index (RSI) 51.79 51.28
Support Level $2.09 $1.04
Resistance Level $2.20 $1.26
Average True Range (ATR) 0.03 0.06
MACD 0.01 -0.00
Stochastic Oscillator 38.89 59.18

Price Performance

Historical Comparison
GEG
PMVP

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: